Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral ...
Please provide your email address to receive an email when new articles are posted on . AMSTERDAM — Unexpectedly high hepatocellular carcinoma recurrence rates were reported among patients who ...
A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...
According to data from eight studies being presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results